業績紹介

2019年 論文

  • Biopsy-diagnosed renal granuloma after intravesical bacillus Calmette-Guerin therapy for bladder carcinoma: a case series and review of the literature.
    Narita K, Akita H, Kikuchi E, Nakahara T, Okuda S, Nakatsuka S, Oya M, Jinzaki M.
    BJR Case Rep. 2019 Nov 15;5(4). pii: bjrcr.20190012. doi: 10.1259/bjrcr.20190012. eCollection 2019 Dec.
  • Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
    Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M.
    Cancer Sci. 2019 Dec 28. doi: 10.1111/cas.14294.
  • Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report.
    Daimon T, Kosaka T, Horinaga M, Saito J, Ueyama Y, Matsuzaki S, Oya M.
    Diagn Pathol. 2019 Dec 16;14(1):135. doi: 10.1186/s13000-019-0915-0.
  • Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.
    Takeda T, Tin AL, Corradi RB, Alvim R, Hashimoto T, Ito Y, Nguyen DP, Mamoor M, Robertson NL, Vargas HA, Benfante NE, Sjoberg DD, Eastham JA, Scardino PT, Fine SW, Oya M, Touijer KA.
    Int J Urol. 2019 Dec 13. doi: 10.1111/iju.14161. [Epub ahead of print]
  • Factors affecting renal function preservation among patients not achieving trifecta after laparoscopic partial nephrectomy for clinical T1a renal masses.
    Takeda T, Komatsuda A, Yanai Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Shinojima T, Asanuma H, Oya M.
    Asian J Endosc Surg. 2019 Dec 9. doi: 10.1111/ases.12776. [Epub ahead of print]
  • Usefulness of contrast-enhanced ultrasonography for diagnosis of renal cell carcinoma in dialysis patients: Comparison with computed tomography.
    Hashimoto M, Ohkuma K, Akita H, Yamada Y, Nakatsuka S, Mizuno R, Oya M, Jinzaki M.
    Medicine (Baltimore). 2019 Nov;98(47):e18053. doi: 10.1097/MD.0000000000018053.
  • ASO Author Reflections: Could Laparoscopic Surgery Have the Same Long-Term Oncological Outcomes as Open Radical Nephroureterectomy in T3N0M0 Upper Tract Urothelial Carcinoma? A Multicenter Cohort Study Adjusted by Propensity Score Matching.
    Shigeta K, Kikuchi E, Oya M.
    Ann Surg Oncol. 2019 Dec;26(Suppl 3):815-816. doi: 10.1245/s10434-019-07996-3. Epub 2019 Oct 28. No abstract available.
  • Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, Sugiyama T, Oya M, Fujii Y, Obara W, Motzer RJ, Uemura H.
    Jpn J Clin Oncol. 2019 Oct 21. pii: hyz132. doi: 10.1093/jjco/hyz132. [Epub ahead of print]
  • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.
    Pathol Int. 2019 Dec;69(12):715-720. doi: 10.1111/pin.12860. Epub 2019 Oct 20.
  • The efficacy of the TachoSil binding suturing technique in laparoscopic partial nephrectomy to prevent the development of pseudoaneurysm.
    Shigeta K, Matsumoto K, Abe T, Komatsuda A, Takeda T, Mizuno R, Kikuchi E, Asanuma H, Arita Y, Akita H, Jinzaki M, Miyajima A, Oya M.
    Asian J Surg. 2019 Oct 16. pii: S1015-9584(19)30793-6. doi: 10.1016/j.asjsur.2019.09.002. [Epub ahead of print]
  • Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
    Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.
    World J Urol. 2019 Sep 26. doi: 10.1007/s00345-019-02970-w. [Epub ahead of print]
  • A comparison of laparoendoscopic single-site surgery versus conventional procedures for laparoscopic donor nephrectomy: a Japanese multi-institutional retrospective study.
    Inoue T, Miura M, Yanishi M, Furukawa J, Sato F, Nitta M, Yoshimura K, Hagiuda J, Shinoda K, Kobayashi T, Miyajima A, Nakagawa K, Oya M, Ogawa O, Mimata H, Kanayama HO, Fujisawa M, Terachi T, Matsuda T, Habuchi T; LESS and RPS Research Group in Japanese Society of Endourology.
    Surg Endosc. 2019 Sep 23. doi: 10.1007/s00464-019-07119-9. [Epub ahead of print]
  • [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
    Oya M, Tajima Y, Kabu K.
    Gan To Kagaku Ryoho. 2019 Sep;46(9):1397-1404. Review. Japanese.
  • Successful perinatal management of a dichorionic diamniotic twin pregnancy in an anaemic kidney transplant patient treated with Darbepoetin alfa: a case report.
    Tamaki S, Shinoda K, Matsumoto T, Morita S, Asanuma H, Yoshida T, Oya M.
    J Obstet Gynaecol. 2019 Sep 3:1-3. doi: 10.1080/01443615.2019.1636776. [Epub ahead of print] No abstract available.
  • A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma.
    Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mikami S, Mizuno R, Oya M.
    Eur Urol Oncol. 2019 Aug 5. pii: S2588-9311(19)30102-6. doi: 10.1016/j.euo.2019.06.021. [Epub ahead of print]
  • Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, Oyama M.
    Anticancer Res. 2019 Aug;39(8):4371-4377. doi: 10.21873/anticanres.13606.
  • Editorial Comment.
    Yazawa S, Oya M, Nakajima Y.
    J Urol. 2019 Nov;202(5):1000. doi: 10.1097/01.JU.0000578560.21169.3f. Epub 2019 Oct 9. No abstract available.
  • Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
    Yanai Y, Kosaka T, Hongo H, Oya M.
    BMC Cancer. 2019 Jul 22;19(1):720. doi: 10.1186/s12885-019-5942-4.
  • Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
    Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M.
    Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051.
  • Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching.
    Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mizuno R, Oya M.
    Ann Surg Oncol. 2019 Oct;26(11):3774-3781. doi: 10.1245/s10434-019-07623-1. Epub 2019 Jul 16.
  • Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy.
    Watanabe K, Kosaka T, Aimono E, Hongo H, Mikami S, Nishihara H, Oya M.
    Clin Genitourin Cancer. 2019 Oct;17(5):e897-e902. doi: 10.1016/j.clgc.2019.06.005. Epub 2019 Jun 13. No abstract available.
  • TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
    Niwa N, Tanaka N, Hongo H, Miyazaki Y, Takamatsu K, Mizuno R, Kikuchi E, Mikami S, Kosaka T, Oya M.
    Lab Invest. 2019 Nov;99(11):1702-1713. doi: 10.1038/s41374-019-0285-y. Epub 2019 Jul 1.
  • Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Takeda T, Benfante NE, Assel M, Mulhall JP, Oya M, Touijer KA.
    Int J Urol. 2019 Sep;26(9):934-935. doi: 10.1111/iju.14043. Epub 2019 Jun 25. No abstract available.
  • Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T, Hongo H, Oya M.
    BMC Cancer. 2019 Jun 11;19(1):562. doi: 10.1186/s12885-019-5782-2.
  • Accidental Hypothermia Treated by Hemodialysis in the Acute Phase: Three Case Reports and a Review of the Literature.
    Murakami T, Yoshida T, Kurokochi A, Takamatsu K, Teranishi Y, Shigeta K, Tamaki S, Morita S, Mizuno R, Oya M.
    Intern Med. 2019 Sep 15;58(18):2743-2748. doi: 10.2169/internalmedicine.1945-18. Epub 2019 Jun 7. Review.
  • Preserved Kidney Volume, Body Mass Index, and Age Are Significant Preoperative Factors for Predicting Estimated Glomerular Filtration Rate in Living Kidney Donors at 1 Year After Donation.
    Shinoda K, Morita S, Akita H, Washizuka F, Tamaki S, Takahashi R, Oguchi H, Sakurabayashi K, Mizutani T, Takahashi Y, Hyodo Y, Itabashi Y, Muramatsu M, Kawamura T, Asanuma H, Kikuchi E, Jinzaki M, Shiraga N, Nakagawa K, Oya M, Shishido S, Sakai K.
    Transplant Proc. 2019 Jun;51(5):1306-1310.doi: 10.1016/j.transproceed.2019.01.142.Epub 2019 May 7.
  • Physical Parameters, Use of Specific Medical Treatments, Nursing Levels, and Activities of Daily Living Are Potential Indicators for Forgoing Maintenance Hemodialysis.
    Yamaguchi N, Yoshida T, Oba M, Nakano R, Saito M, Hirokawa M, Shinmi T, Urasawa C, Oya M.
    Keio J Med. 2019 May 9. doi: 10.2302/kjm.2019-0001-OA. [Epub ahead of print]
  • Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
    Takamatsu K, Mizuno R, Tanaka N, Takeda T, Morita S, Matsumoto K, Kosaka T, Shinojima T, Kikuchi E, Asanuma H, Oyama M, Mikami S, Oya M.
    Int J Clin Oncol. 2019 Sep;24(9):1069-1074. doi: 10.1007/s10147-019-01459-1. Epub 2019 May 7.
  • Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.
    Kaneko G, Shirotake S, Nishimoto K, Miyazaki Y, Ito K, Ito Y, Hagiwara M, Kanao K, Nakagawa K, Momma T, Asano T, Tanaka N, Mizuno R, Oya M, Oyama M.
    Jpn J Clin Oncol. 2019 Aug 1;49(8):780-785. doi: 10.1093/jjco/hyz067.
  • Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer.
    Cancer Sci. 2019 Jun;110(6):1820-1828. doi: 10.1111/cas.14019. Epub 2019 May 13.
  • The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy.
    Takamatsu K, Matsumoto K, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M.
    Urol Oncol. 2019 Sep;37(9):575.e19-575.e25. doi: 10.1016/j.urolonc.2019.03.012. Epub 2019 Apr 6.
  • Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review.
    Takahashi R, Shinoda K, Ishida T, Hamamoto Y, Morita S, Akita H, Kitaoka S, Tamaki S, Asanuma H, Yoshida T, Jinzaki M, Kameyama K, Oya M.
    BMC Nephrol. 2019 Apr 3;20(1):120. doi: 10.1186/s12882-019-1310-5.
  • Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.
    Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H.
    Jpn J Clin Oncol. 2019 Jun 1;49(6):506-514. doi: 10.1093/jjco/hyz026.
  • Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
    Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M.
    Int J Clin Oncol. 2019 May;24(5):554-556. doi: 10.1007/s10147-019-01395-0.
  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.
    Matsumoto K, Akita H, Narita K, Hashiguchi A, Takamatsu K, Takeda T, Kosaka T, Mizuno R, Kikuchi E, Oya M, Jinzaki M.
    Prostate Cancer Prostatic Dis. 2019 Dec;22(4):539-545. doi: 10.1038/s41391-019-0136-3. Epub 2019 Feb 27.
  • [Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].
    Mizuno R, Oya M.
    Gan To Kagaku Ryoho. 2019 Jan;46(1):50-53. Japanese. No abstract available.
  • Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.
    N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.
  • Pre-donation BMI and preserved kidney volume can predict the cohort with unfavorable renal functional compensation at 1-year after kidney donation.
    Shinoda K, Morita S, Akita H, Tamaki S, Takahashi R, Kono H, Asanuma H, Kikuchi E, Jinzaki M, Nakagawa K, Oya M.
    BMC Nephrol. 2019 Feb 8;20(1):46. doi: 10.1186/s12882-019-1242-0.
  • Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
    Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K, Kosaka T, Mikami S, Saya H, Oya M.
    Cancer Sci. 2019 Apr;110(4):1431-1441. doi: 10.1111/cas.13960. Epub 2019 Mar 1.
  • Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma.
    Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Hayashi K, Ebner DK, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors.
    Oncotarget. 2019 Jan 1;10(1):76-81. doi: 10.18632/oncotarget.26539. eCollection 2019 Jan 1.
  • Mutation of GALNTL5 gene identified in patients diagnosed with asthenozoospermia.
    Hagiuda J, Takasaki N, Oya M, Ishikawa H, Narimatsu H.
    Hum Fertil (Camb). 2019 Jan 10:1-8. doi: 10.1080/14647273.2018.1562239. [Epub ahead of print]
  • Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
    Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI.
    BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6.
  • Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
    Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M.
    Int J Clin Oncol. 2019 May;24(5):546-553. doi: 10.1007/s10147-018-01388-5. Epub 2019 Jan 2. Erratum in: Int J Clin Oncol. 2019 Mar 2;:.
  • Immunoglobulin G4-Related Disease Arising from the Bladder Wall.
    Kufukihara R, Niwa N, Mizuno R, Ohara K, Mikami S, Kikuchi E, Oya M.
    Urol Int. 2019;103(4):488-490. doi: 10.1159/000495570. Epub 2018 Dec 13.
  • Is transperitoneal laparoscopic radical nephrectomy suitable for patients with a history of abdominal surgery?
    Yanai Y, Takeda T, Miyajima A, Matsumoto K, Hagiwara M, Mizuno R, Kikuchi E, Asanuma H, Oya M.
    Asian J Endosc Surg. 2019 Oct;12(4):429-433. doi: 10.1111/ases.12673. Epub 2018 Dec 2.
  • Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.
    Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M.
    Jpn J Clin Oncol. 2019 Jan 1;49(1):69-76. doi: 10.1093/jjco/hyy154.
業績紹介